In this video brief, Dr. Jhaveri reviews additional safety data from TROPION-Breast02 showing that exposure-adjusted rates of treatment-related adverse events were lower with first-line Dato-DXd vs chemotherapy in patients with advanced TNBC who are not eligible for immunotherapy. She also reviews the study design of TROPION-Breast06, a phase 3b trial evaluating Dato-DXd prior to chemotherapy in endocrine-refractory HR+/HER2- disease with the potential to move Dato-DXd earlier in the treatment paradigm.
advertisement
Additional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals, L.P. and Daiichi Sankyo, Inc.
Recommended
Details
Presenters
Related
Overview
In this video brief, Dr. Jhaveri reviews additional safety data from TROPION-Breast02 showing that exposure-adjusted rates of treatment-related adverse events were lower with first-line Dato-DXd vs chemotherapy in patients with advanced TNBC who are not eligible for immunotherapy. She also reviews the study design of TROPION-Breast06, a phase 3b trial evaluating Dato-DXd prior to chemotherapy in endocrine-refractory HR+/HER2- disease with the potential to move Dato-DXd earlier in the treatment paradigm.
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals, L.P. and Daiichi Sankyo, Inc.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?